Meeting Transfusion Safety Expectations

ArticleinAnnals of internal medicine 143(7):537-8 · November 2005with1 Read
Impact Factor: 17.81 · DOI: 10.7326/0003-4819-143-7-200510040-00012 · Source: PubMed

    Abstract

    The incredibly rapid adaptation of nucleic acid tests for West Nile virus (WNV), along with declining WNV incidence in many parts of the United States, has allowed blood banks and patients to breathe much easier. However, in this issue, Custer and colleagues provide a careful and circumspect cost-effectiveness analysis of WNV screening in blood banks. Their model shows that from a population perspective, WNV testing is very costly relative to its benefits, which affect relatively few people.